Anti-CCL2-conjugated platelets attenuate early allograft and ischemia-reperfusion injury by inhibiting monocyte infiltration.

Anti-CCL2-conjugated platelets (PLT-aCCL2) attenuate acute liver allograft injury by inhibiting CCR2+ monocyte infiltration in ischemia-reperfusion and orthotopic liver transplantation models.

• Why it matters: CCL2-CCR2 signaling is linked to early allograft dysfunction and subsequent cellular rejection, but the key driver and a targeted way to interrupt it were unclear.
• What they did: Using bulk RNA-seq and single-cell RNA-seq, the study identified persistent CCL2 expression in monocytes during the first post-transplant week, then engineered PLT-aCCL2 to disrupt CCL2-CCR2 signaling.
• The result: In both ischemia-reperfusion injury and orthotopic liver transplantation models, a single intravenous injection of PLT-aCCL2 reduced CCR2+ monocyte infiltration, suppressing inflammatory injury and alleviating acute allograft rejection.

AI summary of the abstract · may contain errors · not medical advice · read the paper.